Abstract: Compounds of formula I ##STR1## wherein X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, X.sub.6, Y, Z and R.sub.1 -R.sub.4 are as defined in the description, have valuable pharmaceutical properties and are especially active against tumours. They are prepared in a manner known per se.

Abstract: 1-Phenyl-3-azabicyclo[3.1.1]-heptane-2,4-diones of the formula ##STR1## in which R.sub.1 represents hydrogen or a saturated or unsaturated, aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, aromatic or aromatic-aliphatic hydrocarbon radical having up to and including 18, preferably up to and including 12, carbon atoms, R.sub.2 represents hydrogen, lower alkyl, sulpho or acyl, R.sub.3 represents hydrogen or lower alkyl and R.sub.4 represents hydrogen, lower alkyl, phenyl or phenyl substituted by --N(R.sub.2)(R.sub.3), and salts of these compounds, have valuable pharmacological properties, are effective as aromatase inhibitors and can therefore be used for the treatment of hormone-dependent diseases, especially mammary carcinoma.

Abstract: 1-Phenyl-3-azabicyclo[3.1.0]hexane-2,4-diones of the formula ##STR1## wherein R.sub.1 is hydrogen, R.sub.2 is hydrogen, sulfo or acyl and R.sub.3 is hydrogen, or R.sub.1 is a saturated or unsaturated aliphatic, cycloaliphatic or cycloaliphatic-aliphatic carbon radical of up to and including 18, preferably of up to and including 12, carbon atoms, R.sub.2 is hydrogen, lower alkyl, sulfo or acyl and R.sub.3 is hydrogen or lower alkyl, and to salts thereof, and salts thereof, have valuable pharmacological properties and are effective aromatase inhibitors. They can therefore be used for the treatment of hormonal diseases, in particular mammary carcinomas.

Abstract: 1-phenyl-3-azabicyclo[3.1.1]-heptane-2,4-diones of the formula ##STR1## in which R.sub.1 represents hydrogen or a saturated or unsaturated, aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, aromatic or aromatic-aliphatic hydrocarbon radical having up to and including 18, preferably up to and including 12, carbon atoms, R.sub.2 represents hydrogen, lower alkyl, sulpho or acyl, R.sub.3 represents hydrogen or lower alkyl and R.sub.4 represents hydrogen, lower alkyl, phenyl or phenyl substituted by --N(R.sub.2)(R.sub.3), and salts of these compounds, have valuable pharmacological properties, are effective as aromatase inhibitors and can therefore be used for the treatment of hormone-dependent diseases, especially mammary carcinoma.

Abstract: A circuit for performing a method melting vitreous materials in an electric furnace wherein the electrodes are supplied with an alternating current of optimal frequency lower than 60 or 50 Hz, respectively, the corrosion of electrodes being minimized. The circuit comprises a cycloconverter which changes a three-phase current supply into a single-phase current with a simultaneous changing of the input mains frequency into an optimal output frequency. The circuit also comprises a device for measuring and/or controlling the direct current component of the low frequency feeding alternating current, in order to stabilize the favorable anticorrosion effect of the low optimal frequency. Further, it comprises a device for the control of the power input of the cycloconverter with respect to the melting temperature in the furnace.

Abstract: The invention relates to novel antigen derivatives comprising an antigen and at least one muramylpeptide covalently bonded thereto, if appropriate via a spacer, to pharmaceutical preparations which contain such compounds and to their use as a vaccine.The novel antigen derivatives produce a pronounced increase in the immuno-response to the antigen, and in particular also a cell-medicated immunity under clinically acceptable conditions of administration.

Abstract: The invention relates to novel antigen derivatives comprising an antigen and at least one muramyl-peptide covalently bonded thereto, if appropriate via a spacer, to pharmaceutical preparations which contain such compounds and to their use as a vaccine.The novel antigen derivatives produce a pronounced increase in the immuno-response to the antigen, and in particular also a cell-medicated immunity under clinically acceptable conditions of administration.

Abstract: The present invention relates to new lipopeptides and in particular to compounds of either of the formulae ##STR1## wherein R.sub.1 and R.sub.2 each represent a saturated or unsaturated aliphatic or mixed aliphatic-cycloaliphatic hydrocarbon radical which has 11-21 C atoms and which is also optionally substituted by oxygen functions, R.sub.3 represents hydrogen or the radical R.sub.1 --CO--O--CH.sub.2 --, where R.sub.1 has the same meaning, R.sub.1 ' is a saturated or unsaturated aliphatic hydrocarbon radical of at least 9 C atoms, which is optionally substituted at one of the C atoms non adjacent to the sulfur atom by a free hydroxyl group or a hydroxyl group esterified with a monobasic carboxylic acid and which is optionally interrupted in the C atoms chain by one or more oxygen atoms, and which hydrocarbon is optionally substituted by a maximum of 2 cycloaliphatic hydrocarbon radicals having 5-8 ring C atoms, or R.sub.1 ' is the radical --CO--R.sub.1 ", wherein R.sub.

Abstract: The invention relates to pharmaceutical preparations that contain an antibiotic and a muramylpeptide of the formula I or a salt thereof, to processes for their manufacture and to a method for increasing the antibiotic effectiveness of antibiotics. ##STR1## In the formula I, X represents carbonyl or carbonyloxy, R.sub.1 represents optionally substituted alkyl or aryl, R.sub.2, R.sub.3, R.sub.4 and R.sub.6 represent hydrogen or lower alkyl, R.sub.5 represents hydrogen, optionally substituted lower alkyl, cycloalkyl, aryl or nitrogen-containing heterocyclyl, or R.sub.4 and R.sub.5 together represent also C.sub.3 -C.sub.4 alkylene, R.sub.7 represents hydrogen or free, esterified or amidated carboxyl, one of the radicals A.sub.1 and A.sub.2 represents a radical of the formula II and the other of the radicals A.sub.1 and A.sub.2 represents optionally substituted or functionally modified hydroxy or amino.

Abstract: Phosphorylmuramyl peptides of the formula ##STR1## are immuno-potentiating. In the formula, R.sub.1 represents optionally substituted alkyl or aryl, R.sub.2, R.sub.4, R.sub.6 and R.sub.7 represent, for example, hydrogen, R.sub.3 represents hydrogen or lower alkyl, R.sub.5 represents, for example, hydrogen, lower alkyl, hydroxy-lower alkyl, amino-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl or aralkyl, or nitrogen-containing heterocyclyl or heterocyclyl-lower alkyl, and one of the radicals A.sub.1 and A.sub.2 represents a radical of the formula (II) ##STR2## In the formula (II), T represents NH or O, Y represents an optionally substituted alkylene group, which may also be interrupted by one or two oxycarbonyl and/or iminocarbonyl groups, and W represents an aliphatic radical or a cycloalkyl or cycloalkenyl radical having more than 6 carbon atoms. The other of the radicals A.sub.1 and A.sub.2 represents free or etherified hydroxy, amino, lower alkylamino or aminocarbonyl-lower alkylamino.

Abstract: Described are derivatives of pyranoses of the formula I, manufacturing processes and intermediates, and their use as medicaments. ##STR1## The pyranose moiety in the compounds of the formula I is derived especially from D-glucose, but alternatively from D-galactose or D-mannose.Characteristic of the compounds of the formula I is the lower alkyl or phenyl-lower alkyl radical R.sub.8, which carries an oxycarbonyl, mercaptocarbonyl or aminocarbonyl group, which is bonded to an aliphatic, cycloaliphaticaliphatic, cycloaliphatic or aromatic hydrocarbon radical R.sub.0, each of which is optionally substituted and which may be interrupted by oxycarbonyl, mercaptocarbonyl and/or iminocarbonyl and which, like the remaining radicals of the formula I, is defined in patent claim 1.

Abstract: The invention relates to muramyl peptide compounds, especially of the formula ##STR1## in which R.sub.1 represents, for example, alkyl or phenyl,R.sub.3 represents, for example, hydrogen or methyl andR.sub.5 represents, for example, hydrogen or lower alkyl optionally substituted, for example, by hydroxy, mercapto, or methylthio,and in which one of the radicalsA.sub.1 and A.sub.2 represents a group of the formula ##STR2## in which T represents the group of the formula -NH or -O, andY represents an alkylene radical optionally interrupted by a radical of the formula -CO-O- or -CO-NH-,and in whichW represents hydrogen andZ represents a hydroxy-substituted ethyl group, wherein at least one hydroxy group is esterified by a long-chained acyl radical orW and Z represent hydroxymethyl, wherein hydroxy is esterified by a long-chained acyl radical,and the other of the radicals A.sub.1 and A.sub.2 represents optionally etherified hydroxy or optionally substituted amino.

Abstract: The invention relates to novel antigen derivatives comprising an antigen and at least one muramylpeptide covalently bonded thereto, if appropriate via a spacer, to pharmaceutical preparations which contain such compounds and to their use as a vaccine.The novel antigen derivatives produce a pronounced increase in the immuno-response to the antigen, and in particular also a cell-medicated immunity under clinically acceptable conditions of administration.

Abstract: Phosphorylmuramyl peptides of the formula ##STR1## are immuno-potentiating. In the formula, R.sub.1 represents optionally substituted alkyl or aryl, R.sub.2, R.sub.4, R.sub.6 and R.sub.7 represent, for example, hydrogen, R.sub.3 represents hydrogen or lower alkyl, R.sub.5 represents, for example, hydrogen, lower alkyl, hydroxy-lower alkyl, amino-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl or aralkyl, or nitrogen-containing heterocyclyl or heterocyclyl-lower alkyl, and one of the radicals A.sub.1 and A.sub.2 represents a radical of the formula (II) ##STR2## In the formula (II), T represents NH or O, Y represents an optionally substituted alkylene group, which may also be interrupted by one or two oxycarbonyl and/or iminocarbonyl groups, and W represents an aliphatic radical or a cycloalkyl or cycloalkenyl radical having more than 6 carbon atoms. The other of the radicals A.sub.1 and A.sub.2 represents free or etherified hydroxy, amino, lower alkylamino or aminocarbonyl-lower alkylamino.

Abstract: The present invention relates to new nitroso-urea derivatives, particularly to N.sub.1 -glucofuranosid-6-yl-N.sub.3 -nitroso-ureas, of the general formula I ##STR1## wherein anyone of R.sub.1, R.sub.2, R.sub.3 and R.sub.5 represent hydrogen, optionally substituted alkyl, aralkyl or acyl, or R.sub.1 and R.sub.2 together or R.sub.3 and R.sub.5 together also represent alkylidene or cycloalkylidene, and R.sub.6 represents optionally substituted alkyl; and to processes for producing them.

Abstract: The invention relates to novel 1,6-anhydro-.beta.-D-hexopyranose derivatives of the formula I ##STR1## in which R.sub.2 is hydrogen, methyl or aromatic acyl, R.sub.3 and R.sub.4 are alkyl, alkenyl or aralkyl and one of the radicals R.sub.3 and R.sub.4 is also an aroyl radical and R.sub.4 can also be hydrogen, with the proviso that the radicals R.sub.3 and R.sub.4 together contain at least 3 carbon atoms and, if R.sub.4 is the benzyl radical, the radical R.sub.3 contains at least 2 carbon atoms, and, if one of the radicals R.sub.3 and R.sub.4 is an aroyl radical, R.sub.2 is hydrogen.These compounds especially the 1,6-anhydro-3,4-di-O-benzyl-.beta.-D-glucopyranose or the 1,6-anhydro-.beta.-D-glucopyranose, can be used as fibrinolytic agents and thrombolytic agents.

Abstract: The invention relates to furanose-O-pyridylcarboxylic acid esters, such as the ethyl-2-O-methyl-3,5,6-tri-O-nicotinoyl-D-glucofuranoside, which have anti-inflammatory activity and are fibrinolysis activators. They can be used for the treatment of rheumatic and neuralgic complaints, and especially for the topical percutaneous treatment of localized inflammatory processes.